Current through October 17, 2024
Section 12 AAC 14.570 - MedicationsA certified direct-entry midwife may not administer restricted drugs or medications except for the following, and only if the certified direct-entry midwife has documented the training and skills demonstrating competence to administer them as required in 12 AAC 14.560:
(1) xylocaine hydrochloride, one or two percent, administered by infiltration, for the postpartum repair of tears, lacerations, and episiotomy;(2) cetacaine, applied topically, for the postpartum repair of tears, lacerations, and episiotomy;(3) vitamin K, administered by intramuscular injection, for the prevention of acute and late onset hemorrhagic disease of the infant;(4) Rh immune globulin, administered by intramuscular injection, for an unsensitized client with Rh negative type blood to prevent Rh disease;(5) eye prophylaxis as required by 7 AAC 27.111;(6) oxytocin, administered by intramuscular injection or intravenously after delivery of the neonate, for the prevention or treatment of postpartum hemorrhage;(7) medications for the control and treatment of postpartum hemorrhage, including uterotonic agents, oxytocin, methylergonovine, carboprost tromethamine, tranexamic acid, and misoprostol(8) lactated ringers, plain or with dextrose five percent, or normal saline, up to 2,000 milliliters administered intravenously to a client who would benefit from hydration;(9) antibiotic intravenous therapy treatment for Group B Streptococci in accordance with the United States Department of Health and Human Services, Centers for Disease Control and Prevention's Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC,revised as of August 16, 2002 and adopted by reference, except that vancomycin may not be administered;(10) epinephrine for allergic reaction or anaphylactic shock;(11) diphenhydramine administered by intramuscular injection or intravenously for allergic reaction or anaphylactic shock;(12) an anti-diarrheal agent, including loperamide or diphenoxylate/atropine.Eff. 5/11/94, Register 130; am 5/2/2004, Register 170; am 10/18/2007, Register 184; am 3/2/2011, Register 197; am 6/29/2013, Register 206; am 9/9/2016, Register 219, October 2016; am 2/22/2023, Register 245, April 2023Authority:AS 08.65.030
AS 08.65.190